Posted by King K
on July 23, 2026
The one thing to understand. The 2026 DEA action is aimed at one molecule, 7-hydroxymitragynine (7-OH), when it is concentrated above a set threshold or made synthetically. It is not aimed at mitragynine, the alkaloid that actually defines kratom extract. A lab-tested, mitragynine-forward extract shot and an "enhanced 7-OH" tablet are two different products, even when they sit on the same shelf.
Extract customers have a fair question right now. If the government is scheduling a kratom compound, does that mean extract shots are on the way out?
The honest answer is that it depends entirely on which compound the product is built around. That is not a dodge. It is the actual dividing line the rule draws, and once you see the chemistry, the whole thing makes sense.
Two Molecules, One Leaf
Kratom leaf contains dozens of alkaloids. Two of them matter for this conversation.
Mitragynine is the big one. It is the most abundant alkaloid in the leaf by a wide margin, and it is what a real kratom extract concentrates. When a label says an extract is standardized to a mitragynine percentage, that is the number doing the work.
7-hydroxymitragynine, or 7-OH, is a minor character in the leaf. It occurs in trace amounts, under two percent of the total alkaloids and usually far less. Your body also produces a little of it after you consume mitragynine, as a natural metabolite. In the leaf itself, it is a bit player. The National Center for Complementary and Integrative Health has a plain-language overview of kratom and its alkaloids if you want the baseline science.
Here is the catch that created this entire market. 7-OH can be produced from mitragynine in a single chemical step. So a manufacturer can take ordinary leaf material, run a reaction, and end up with a product that is mostly 7-OH at a concentration nature never makes. That is not an extract in the traditional sense. It is closer to a synthesized drug.
Why Concentration Changes Everything
Chemically, synthetic 7-OH and the trace 7-OH in leaf are the same molecule. The Federal Register notice is clear about that. What is different is the dose and the context.
In whole leaf, 7-OH rides along with mitragynine and everything else. The mix is self-limiting. Pull 7-OH out, concentrate it, and put it in a tablet by itself, and you get an unattenuated, high-potency opioid-like effect that the leaf simply does not deliver. That is why regulators treated the isolated compound as a distinct safety problem rather than treating kratom as a whole. The reasoning is laid out in the DEA's own notice of intent, which is worth reading if you sell or use extract.
Peer-reviewed pharmacology backs the distinction. Research in journals such as Frontiers in Pharmacology has spent years mapping how mitragynine and 7-OH act at different strengths on the same receptors, which is exactly why a rule can single out one and not the other.
Where the Line Is Drawn
The 2026 order is specific. It covers 7-OH above a threshold, defined a few ways:
- Botanical material with more than 0.050 percent 7-OH on a dry weight basis.
- Synthetic material above that same 0.050 percent by weight or volume, or more than 1.00 milligram of 7-OH in a single item.
- Leaf material that has been further processed into extracts, concentrates, edibles, or pressed pills in a way that pushes 7-OH past those limits.
Read that last point carefully, because it is the one extract sellers need to sit with. The word "extract" is not a free pass. If an extract has been cooked, converted, or spiked so that its 7-OH content clears the threshold, it is covered. If it is a genuine mitragynine extract that keeps 7-OH in trace territory, it is not.
The rule is measuring the molecule, not the marketing.
The Three Synthetics Nobody Should Be Selling
Alongside 7-OH, the DEA moved on three lab-made cousins that do not occur in the plant at all:
| Compound | What it is |
|---|---|
| Mitragynine pseudoindoxyl (MP) | A chemical rearrangement product of 7-OH |
| MGM-15 | Dihydro-7-hydroxymitragynine, a synthetic derivative |
| MGM-16 | The 9-fluoro derivative of 7-OH, another synthetic |
These have shown up in candies, tablets, and liquid shots, often labeled as "kratom extract" even though there is nothing botanical about them. If you have ever wondered how some gas station shot could possibly be that strong, this is frequently the answer. Any brand still selling these is the reason the rule exists.
What This Means if You Buy Extract Shots
Strip away the noise and it comes down to one habit: read the alkaloid panel.
Mitragynine should lead
A legitimate extract is defined by its mitragynine content. That number should be front and center on the certificate of analysis.
7-OH should be a trace figure
On a real leaf-based extract, 7-OH stays small. If a product leads with 7-OH milligrams instead, or hides its 7-OH number entirely, treat that as a warning, not a feature.
"Strong" is not the same as "high 7-OH"
A potent mitragynine extract can be a serious product without touching the threshold. Potency and 7-OH content are two different things, and the good brands compete on the first without chasing the second.
Frequently Asked Questions
Are all kratom extracts banned now?
No. The action covers 7-OH above a threshold. A mitragynine-based extract that keeps 7-OH in trace amounts is a different product and is not the target.
Is mitragynine being scheduled?
No. Mitragynine is not named in the 2026 action. The order is about 7-OH and three synthetic derivatives of it.
My shot says "extract." Is it safe from the rule?
Not automatically. What matters is the 7-OH content, not the word "extract." Check the certificate of analysis. If 7-OH clears the threshold, the product is covered even if it is labeled an extract.
Why single out 7-OH if it comes from the same plant?
Because concentration and isolation change how it behaves. In the leaf, 7-OH is a trace alkaloid balanced by mitragynine and others. Pulled out and concentrated, it acts like a potent opioid, which is the safety concern driving the rule.
When could this take effect?
The temporary scheduling order could be issued no earlier than August 5, 2026, and would run for two years if put in place.
The Takeaway
This is not a war on extract. It is a line between a real mitragynine extract and a concentrated 7-OH product wearing the extract label. The first has always been what King K makes. The second is what the rule is built to remove.
Every King K extract is standardized around mitragynine and lab tested batch by batch, with the full alkaloid panel on the certificate of analysis so you can see the 7-OH number for yourself. In a market that is about to get a lot more serious about that number, showing our work is the whole point.
This article is general information, not legal or medical advice. Kratom regulations vary by jurisdiction and are changing quickly. Verify the current rules where you live and sell. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
